Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
biotechnology company
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
24 mars 2025 16h30 HE
|
Serina Therapeutics, Inc.
HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
GRI Bio Participates in a Virtual Investor CEO Connect Segment
18 mars 2025 09h05 HE
|
GRI Bio, Inc.
Access the CEO Connect segment here LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative...
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
17 mars 2025 08h05 HE
|
GRI Bio, Inc.
Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively Cash runway expected to fund operations into Q2 2025, including interim data...
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
20 févr. 2025 08h30 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company...
Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
22 janv. 2025 09h00 HE
|
BIOXYTRAN, INC.
- Repurchasing all convertible note overhang, and - Funding pre-clinical and clinical trials - Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE...
Serina Therapeutics Announces Sale of UniverXome Subsidiary
15 janv. 2025 16h05 HE
|
Serina Therapeutics, Inc.
- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a...
Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting
07 janv. 2025 09h00 HE
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral...
FOXO TECHNOLOGIES INC. ANOUNCES DETAILS OF ITS 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2024
23 déc. 2024 09h25 HE
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold its 2024 Annual General Meeting of its Shareholders at 9:30 am...
FOXO TECHNOLOGIES INC. ANNOUNCES THAT STOCKHOLDERS EQUITY IS GREATER THAN $4M, WHICH IS REQUIRED TO MEET THE CONTINUED LISTING REQUIREMENTS OF THE NYSE AMERICAN EXCHANGE
16 déc. 2024 12h32 HE
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”) announces that recent transactions have led to the Company having...
FOXO TECHNOLOGIES INC. ANNOUNCES RESTRUCTURING AND CAPITAL RAISING TRANSACTIONS AND APPOINTS SEAMUS LAGAN AS CHIEF EXECUTIVE OFFICER
11 déc. 2024 08h00 HE
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Dec. 11, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”) announces a series of restructuring and capital raising transactions which...